X4 Pharmaceuticals, Inc. (XFOR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paula Ragan Ph.D. | CEO, President & Director | 963.58k | -- | 1970 |
| Mr. Adam S. Mostafa | CFO, Treasurer & Corporate Secretary | 699.18k | -- | 1980 |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer | 661.59k | -- | 1961 |
| Dr. Richard Peters M.D., Ph.D. | Founder | -- | -- | 1963 |
| Dr. Renato T. Skerlj Ph.D. | Founder | -- | -- | -- |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corporate Advisory Board | -- | -- | 1971 |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer | -- | -- | 1964 |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research | -- | -- | 1948 |
| Mr. Mark Baldry M.B.A. | Chief Commercial Officer | -- | -- | 1964 |
X4 Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 93
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Corporate Governance
Recent Events
- Apr 05, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 07, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 31, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing